Compare GBDC & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBDC | TMDX |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2010 | 2019 |
| Metric | GBDC | TMDX |
|---|---|---|
| Price | $13.57 | $122.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.83 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 2.0M | 664.3K |
| Earning Date | 02-03-2026 | 10-29-2025 |
| Dividend Yield | ★ 11.50% | N/A |
| EPS Growth | 4.09 | ★ 170.70 |
| EPS | 1.42 | ★ 2.54 |
| Revenue | ★ $870,777,000.00 | $566,354,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | N/A | $20.49 |
| P/E Ratio | ★ $9.58 | $47.97 |
| Revenue Growth | 20.16 | ★ 41.20 |
| 52 Week Low | $12.68 | $55.00 |
| 52 Week High | $16.01 | $156.00 |
| Indicator | GBDC | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 42.29 |
| Support Level | $13.44 | $121.00 |
| Resistance Level | $13.65 | $133.29 |
| Average True Range (ATR) | 0.20 | 4.84 |
| MACD | -0.02 | -0.91 |
| Stochastic Oscillator | 24.77 | 21.93 |
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.